Prescriptions of Eisai’s Aricept To New Patients Below 50%
This article was originally published in PharmAsia News
According to research carried out by the Japan Medical Information Research Institute, the share of new patients being prescribed Eisai’s Alzheimer drug Aricept in August 2012 decreased to just 45% due to the increase in generic drugs and the end of limits to long-term prescriptions.
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.